Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CERT
stocks logo

CERT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
103.67M
+3.3%
0.102
-31.98%
110.91M
+4.63%
0.142
+1.09%
111.11M
+6.26%
0.136
+93.84%
Estimates Revision
The market is revising Downward the revenue expectations for Certara, Inc. (CERT) for FY2025, with the revenue forecasts being adjusted by -0.78% over the past three months. During the same period, the stock price has changed by -9.03%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.59%
In Past 3 Month
Stock Price
Go Down
down Image
-9.03%
In Past 3 Month
Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 13.71 USD with a low forecast of 9.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 13.71 USD with a low forecast of 9.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 9.570
sliders
Low
9.00
Averages
13.71
High
16.00
Current: 9.570
sliders
Low
9.00
Averages
13.71
High
16.00
Rothschild & Co Redburn
Buy
initiated
$10
2025-11-21
Reason
Rothschild & Co Redburn
Price Target
$10
2025-11-21
initiated
Buy
Reason
Rothschild & Co Redburn initiated coverage of Certara with a Buy rating and $10 price target. The firm views Certara as the leader in biosimulation, which it says can aid the discovery of potential drug targets and reduce the need for early stage clinical work. Certara needs to increase penetration into discovery and preclinical phases, and it acquisition of Chemaxon boosts its presence in these areas, the analyst tells investors in a research note.
BMO Capital
Market Perform
initiated
$9
2025-11-12
Reason
BMO Capital
Price Target
$9
2025-11-12
initiated
Market Perform
Reason
BMO Capital initiated coverage of Certara with a Market Perform rating and $9 price target. BMO remains a big believer in the longer-run opportunities associated with modernizing the currently antiquated drug development process, but would like to see more evidence that these initiatives are gaining traction before getting more constructive on the stock, the analyst tells investors in a research note.
Baird
Joe Vruwink
Neutral
downgrade
$13 -> $12
2025-11-07
Reason
Baird
Joe Vruwink
Price Target
$13 -> $12
2025-11-07
downgrade
Neutral
Reason
Baird analyst Joe Vruwink lowered the firm's price target on Certara to $12 from $13 and keeps a Neutral rating on the shares. The firm updated its model following results where guidance was revised lower on services bookings slowdown.
Barclays
Luke Sergott
Overweight
maintain
$16 -> $14
2025-11-07
Reason
Barclays
Luke Sergott
Price Target
$16 -> $14
2025-11-07
maintain
Overweight
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Certara to $14 from $16 and keeps an Overweight rating on the shares. The firm makes no changes to its long-term thesis following the earnings report. The business has a solid setup into 2026, the analyst tells investors in a research note.
Craig-Hallum
Buy
initiated
$16
2025-09-29
Reason
Craig-Hallum
Price Target
$16
2025-09-29
initiated
Buy
Reason
Craig-Hallum initiated coverage of Certara with a Buy rating and $16 price target.
Craig-Hallum
Matthew Hewitt
initiated
$16
2025-09-29
Reason
Craig-Hallum
Matthew Hewitt
Price Target
$16
2025-09-29
initiated
Reason
As previously reported, Craig-Hallum analyst Matthew Hewitt initiated coverage of Certara with a Buy rating and $16 price target. The firm likes the overlap of near-term prospects and its long-term economics. Moreover, Craig-Hallum views the company as being at the center of the pharma/biotech rebound, offering investors a unique opportunity to participate in the overall increase in R&D investment in the coming quarter/years. With shares currently trading at 14.3-times 2026EV/EBITDA, the firm believes the current valuation offers an attractive entry point for investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Certara Inc (CERT.O) is 18.49, compared to its 5-year average forward P/E of 49.67. For a more detailed relative valuation and DCF analysis to assess Certara Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
49.67
Current PE
18.49
Overvalued PE
85.39
Undervalued PE
13.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
25.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
37.37
Undervalued EV/EBITDA
13.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.68
Current PS
0.00
Overvalued PS
13.08
Undervalued PS
4.27
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CERT News & Events

Events Timeline

(ET)
2025-12-02
10:50:00
FDA Proposes Guidance for Streamlined Safety Assessments of Monospecific Antibodies
select
link
2025-11-06 (ET)
2025-11-06
16:53:55
Certara projects FY25 adjusted EPS between 45c and 47c, surpassing consensus estimate of 43c.
select
2025-11-06
16:52:41
Certara announces Q3 adjusted EPS of 14 cents, surpassing consensus estimate of 11 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
02:00 AMNASDAQ.COM
ArrowMark Reduces Stake in Alight as Concerns Rise Over Recurring Revenue Strategy

  • ArrowMark's Share Sale: ArrowMark Colorado Holdings LLC sold 9,793,024 shares of Alight, reducing its position by approximately $74.46 million, which now represents 0.48% of its total assets under management.

  • Alight's Business Overview: Alight is a technology-driven provider of digital HR, payroll, and business solutions, focusing on large enterprises and generating revenue through long-term contracts and recurring employer solutions.

  • Market Reaction and Implications: The significant reduction in ArrowMark's stake signals potential internal issues within Alight that the market may not have fully recognized, prompting investors to reassess the stock's decline.

  • Future Considerations for Alight: The company's ability to stabilize margins, protect client retention, and increase recurring revenue will be crucial for its recovery and could determine if the current share price represents a low point in its valuation.

[object Object]
Preview
9.5
11-29Newsfilter
Cerrado Gold Reports 13,832 GEO Production in Q3 2025
  • Gold Production Growth: Cerrado Gold produced 13,832 Gold Equivalent Ounces (GEO) in Q3 2025, a decrease from 16,604 GEO in Q3 2024, primarily due to a shift in CIL operations towards processing lower-grade ore, impacting overall output.
  • Financial Performance Improvement: The company reported revenue of $41 million for Q3 2025, up from $36.67 million in Q3 2024, driven by an increase in average realized gold price to $3,182 per ounce, despite a decline in sales volume.
  • Cash Flow Status: Adjusted EBITDA for Q3 stood at $11.78 million, indicating ongoing improvement in operational cash flow, although a net loss of $12.18 million was recorded, largely due to increased tax expenses.
  • Future Outlook: Cerrado Gold maintains its 2025 production guidance of 50,000 to 55,000 GEO, with expectations that the introduction of higher-grade underground ore will gradually reduce production costs, enhancing future profitability.
[object Object]
Preview
7.5
11-29Globenewswire
Cerrado Gold Reports 13,832 GEO Production in Q3 2025 with $11.8M EBITDA
  • Gold Production Increase: Cerrado Gold produced 13,832 Gold Equivalent Ounces (GEO) in Q3 2025, representing a 21% increase from 11,437 GEO in Q2, showcasing significant operational efficiency improvements at its mining sites.
  • Cash Flow Performance: The company reported an adjusted EBITDA of $11.8 million for Q3, reflecting enhanced profitability amid rising gold prices, despite facing challenges from increased production costs.
  • Exploration Program Expansion: Cerrado has expanded its initial 20,000-meter exploration program to 50,000 meters, aiming to accelerate exploration efforts through the introduction of new drill rigs, thereby laying the groundwork for future resource growth.
  • Significant Project Progress: The feasibility studies for the Lagoa Salgada and Mont Sorcier projects are nearing completion, expected to be released in early 2026, further strengthening the company's competitive position in the polymetallic and high-purity iron markets.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Certara Inc (CERT) stock price today?

The current price of CERT is 9.57 USD — it has decreased -1.14 % in the last trading day.

arrow icon

What is Certara Inc (CERT)'s business?

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

arrow icon

What is the price predicton of CERT Stock?

Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 13.71 USD with a low forecast of 9.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Certara Inc (CERT)'s revenue for the last quarter?

Certara Inc revenue for the last quarter amounts to 104.62M USD, increased 10.33 % YoY.

arrow icon

What is Certara Inc (CERT)'s earnings per share (EPS) for the last quarter?

Certara Inc. EPS for the last quarter amounts to 0.01 USD, decreased -200.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Certara Inc (CERT)'s fundamentals?

The market is revising Downward the revenue expectations for Certara, Inc. (CERT) for FY2025, with the revenue forecasts being adjusted by -0.78% over the past three months. During the same period, the stock price has changed by -9.03%.
arrow icon

How many employees does Certara Inc (CERT). have?

Certara Inc (CERT) has 1487 emplpoyees as of December 05 2025.

arrow icon

What is Certara Inc (CERT) market cap?

Today CERT has the market capitalization of 1.52B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free